(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

This special report examines a new oral cholesterol medication, Enlycetide, developed by Merck. The pill, an investigational PCSK9 inhibitor, has shown significant results in Phase 3 trials by ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...

Merck has unveiled a groundbreaking cholesterol-lowering pill, enlicitide, which could transform treatment for millions of Americans struggling with high LDL cholesterol. The once-daily oral ...

Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time Presentations across hypercholesterolemia ...

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial ...

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...